Venrock Healthcare Capital Partners III, L.P. is 10% Owner at KalVista Pharmaceuticals, Inc. (KALV). They have made 8 open-market trades across 3 companies since 2018, most recently 2026-03-26.
CIK 0001738048
6 open-market purchases totalling $10.9M since 2018, against 2 sales. Across 5 scored buys the stock is down 5.6% at ninety days, and 6.2 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| KALV | 5,089,354 | $137.3M |
| UMRX | 4,004,273 | $9.4M |
| BLPH | 6,768,183 | $694K |
| Total | $147.4M |
Shares reported on the most recent Form 4, priced at the 2026-03-27 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 33% | 20% |
| Avg Move | -0.8% | +4.3% | -5.6% |
| Alpha | -2.0% | +4.5% | -6.2% |
| Scored | 6 | 6 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KALV | SELL | 2026-03-25 | 2026-03-27 | $17.20 | $3.7M | +5.2% | +1.1% | N/A |
| KALV | BUY | 2025-02-07 | 2025-02-11 | $9.26 | $1.9M | +10.0% | +30.2% | +29.4% |
| KALV | BUY | 2024-01-30 | 2024-02-01 | $14.47 | $2.5M | -4.6% | -9.8% | -21.7% |
| KALV | BUY | 2024-01-25 | 2024-01-29 | $13.92 | $1.4M | +3.5% | -6.9% | -23.5% |
| KALV | BUY | 2024-01-08 | 2024-01-10 | $12.51 | $2.8M | -1.8% | +25.6% | -7.3% |
| UMRX | BUY | 2020-08-14 | 2020-08-18 | $2.48 | $1.4M | -3.7% | -4.0% | N/A |
| BLPH | SELL | 2019-10-24 | 2019-10-28 | $0.48 | $1.0M | +4.2% | +1.1% | -10.5% |
| BLPH | BUY | 2018-09-10 | 2018-09-12 | $1.16 | $786K | -8.3% | -9.2% | -5.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.